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net searches of relevant websites (such as different health technology assessment 
agencies in Europe). Researchers conducted discussions with payers and biopharma 
experts to identify the perceived differences in pricing negotiations between coun-
tries. RESULTS: There are distinctive differences in the approaches to pricing nego-
tiations between payers in the US and Europe. These lead to determinable patterns 
in the methods that biopharma companies leverage to price their products and in 
the methods that payers use, by either working with the biopharma companies or 
creating reimbursement mechanisms to guide the appropriate utilization of these 
products. European payers have more central negotiating leverage and more for-
malized health technology assessments, which enable them to negotiate and even 
mandate prices and/or develop outcome-based contracts. CONCLUSIONS: Unlike 
European payers, most US payers do not have the support of similar government-
backed organizations for negotiating price, and most cannot optimally leverage 
health technology assessments. This forces US payers to seek more creative ways of 
managing the utilization of products through medical policies, prior authorizations 
and creative reimbursement methods.
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OBJECTIVES: Prices of medicines differ across EU Member States due to factors, 
some of which are beyond responsibilities of companies. These differences include: 
wholesaler or pharmacy margins, sales tax, pack sizes, distribution channels, 
exchange rate fluctuations, and perhaps most importantly, price-setting processes, 
but also national health and pharmaceutical policies and priorities. Current EU 
transfer pricing rules only address process rather than the resulting levels of pric-
ing and reimbursement. Member States compare and reference price with each 
other (so called ‘International Reference Pricing’ or IRP). We aim to demonstrate 
that companies need to employ a range of different mechanisms to mitigate the 
effects of IRP. METHODS: We review how legislation and case law, including that 
relating to parallel trade or grey market, reinforces national rights to set prices. 
Current price constraints and their interpretation are considered. We then consider 
forthcoming proposals and the extent to which they may lead to greater pricing 
consistency. RESULTS: Based on a review of all nine cases that have proceeded to 
the EU courts, the principle of EU member state discretion in terms of price set-
ting seems currently sacrosanct and it is unlikely that the legislators will be able 
to change this position. In order to balance the respective interests of the industry 
and member states, member states should allow differential pricing; restrict IRP to 
economically comparable Member States; exclude from IRP those elements related 
to pharmaceutical regulation and policies, which are country-specific and likely to 
distort price comparisons; and exclude from IRP and free movement provisions, 
those countries under austerity measures. CONCLUSIONS: Currently, manufac-
turers have limited strategies in terms of price corridors and the like; it seems 
therefore, that more pragmatic solutions will need to be considered at an EU level 
and supported by the Courts.
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OBJECTIVES: In the absence of randomized controlled trials (RCTs) for informing 
clinical effectiveness, manufacturers need to rely on alternative methods for the 
generation of clinical evidence for HTA purposes. As the body of evidence based on 
observational study designs grows, there is a need to understand whether and how 
non-randomized evidence can be incorporated into HTAs globally. The aim of this 
study was to collate and compare published HTA guidance on the use and accept-
ance of non-randomized evidence to inform clinical effectiveness. METHODS: 
Guidelines referring to methods for economic evaluation in the UK, Ireland, 
Australia, Canada, and Germany, were searched for information on the use of non-
randomized evidence to demonstrate clinical effectiveness. Technology appraisals 
and reports from evidence review groups (ERGs) (published 2004–2014) in the oncol-
ogy setting, were assessed to identify circumstances in which non-randomized evi-
dence was submitted in HTAs, and to understand how this evidence was considered 
by ERGs. RESULTS: A lack of clear guidance was found regarding when and how 
non-randomized evidence can be used to support HTAs. Although the majority of 
HTAs request that a systematic search for non-RCT data be conducted, few HTAs 
considered non-randomized evidence relevant to clinical effectiveness outcomes. 
Observational data were submitted to HTA bodies in order to: complement and 
extrapolate RCT evidence, test the integrity of evidence synthesis networks, and 
inform long-term safety outcomes. Feedback regarding the appropriateness of 
observational data was minimal or absent in many ERG reports. CONCLUSIONS: 
There is a need for HTA bodies to provide clearly defined guidance regarding the 
use and appropriateness of observational data for HTA purposes. Currently, there 
is no clear consensus on the value that non-randomized evidence can offer from 
a HTA perspective.
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OBJECTIVES: The study aims to assess the perspectives of different healthcare 
stakeholders on the current incremental cost-effectiveness ratio (ICER) thresh-
olds and understand if these are still considered appropriate for their intended 
model was employed to estimate factors associated with where a new drug was 
reimbursed by NHI and its reimbursement lag. RESULTS: We found that for new 
drugs in Taiwan, the median of marketing lag was 26.84 month while the median of 
reimbursement lag was 11.83 months. About 84% of new drugs were reimbursed by 
NHI. The reimbursement decision were mainly associated with the characteristics 
of medications, including their types of therapy and innovation categories. The 
price-related factors were significantly related with the reimbursement lag but not 
whether medications were reimbursed. CONCLUSIONS: By examining the barriers 
at different stages from drug approval to NHI reimbursed, this study provided dif-
ferent perspectives for health policy makers to examine issues on drug approval, 
health care resource allocation, and quality of medical care.
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OBJECTIVES: In Germany, the reimbursement and pricing of innovative in-patient 
drugs and devices is managed through the NUB application process. These applica-
tions are submitted by the hospital stakeholder and are approved or rejected by the 
Institute for the Hospital Remuneration System (InEK). The objective of this research 
was to assess the NUB trends in Germany in 2012-2014. METHODS: We developed 
a database of NUB approvals and rejections based on the Institute for the Hospital 
Remuneration System’s (InEK )’s reports. All information was extracted into Excel 
format. The following data was extracted: product name, indication, year of submis-
sion, number of NUB applications submitted, status score, type of evidence available 
and lack of evidence for NUB rejection. Additionally, the number of re-applications 
and re-rejections were also analyzed. RESULTS: In 2013 and 2014, a total of 21264 
and 25634 NUB applications were submitted for 612 and 613 medical products, 
respectively. Of these applications in 2013 and 2014, 10% and 16% were approved 
for NUB (as Status 1) and 82% and 75% were rejected (as Status 2), respectively. In 
2014, the median number of hospital applications for NUBs with Status 1 and Status 
2 were 37 and 3, demonstrating the importance of hospital participation for seek-
ing NUB approval. Among approved NUBs, 37% of the applications were for drugs 
and 63% were for devices. Interestingly, the median NUB hospital applications for 
approved drugs was 192, while for devices, the median was 9 applications. In 2014, 
447 NUB applications for products were re-submitted, of which 5 were approved and 
the remaining were re-rejected. The evidence requirements analysis suggests the 
need for hospital focused economic data. CONCLUSIONS: The NUB process plays 
a critical role in market access for in-patient drugs and devices. For approval, two 
key components are: hospital focused economic evidence and provider stakeholder 
involvement.
PHP110
tHE PotEntial imPact of PricE adjUstmEnts of a nEW tHEraPy in 
gErmany on otHEr coUntriEs: a simUlation modElling ExErcisE
Stoykova B.1, Walzer S.2, Dröschel D.2, Zah V.3
1Daiichi Sankyo Development, Gerard’s Cross, UK, 2MArS Market Access & Pricing Strategy 
GmbH, Weil am Rhein, Germany, 3ZRx Outcomes Research Inc., Mississauga, ON, Canada
OBJECTIVES: International Reference Pricing (IRP) is a key cost-containment tool 
for health care payers across the world. IRP may apply either fixed or flexible rules 
to calculate the price of branded drugs. Typically there is no negotiation between 
manufacturers and the IPR body. In the context of the German AMNOG price negotia-
tions and the role of Germany as a key referenced country, there is dearth of real-life 
evidence on the international impact of the AMNOG law. METHODS: The publicly 
available IRP rules were screened and evaluated systematically. Based on these find-
ings an IRP model was developed to simulate scenarios of price agreements for a 
new drug between the German Head Association of the Statutory Health Insurance 
Companies and the manufacturer. The impact of the price agreement on other coun-
tries was analyzed based on the existing IRP rules. RESULTS: We simulated a hypo-
thetical price dataset for a branded drug X with all prices set at 100 euro to limit the 
impact to Germany only. A 25% price drop in Germany would lead to a range of 32.5% 
reduction in Egypt and almost 1% in Austria. The largest impact in Europe would 
be in France, Romania, Russia, Slovenia, Luxembourg (-25%), followed by Norway 
and Greece (-8.33%), the Netherlands (-6.25%), Switzerland, Ireland and Denmark. A 
price drop of 50% in Germany would double the impact with the exception of Egypt 
(-55%). However, a limited impact was observed if the price increase in Germany was 
25%.That would lead to 6.25% increase in the Netherlands, 4.17% in Switzerland, 
2.78% in Ireland and Denmark, and about 1% increase in Austria. CONCLUSIONS: 
Price negotiations in Germany could potentially impact the price of new branded 
therapies in other countries. This could ultimately lead to a price-downward spiral 
with a negative impact on innovation and drug development in Europe.
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OBJECTIVES: In recent years, the pharmaceutical industry has received approval 
in the US and Europe for several products that are unique, meet previously unmet 
needs, and yield important reductions in mortality and morbidity. Frequently, these 
products are orphan and even ultra-orphan drugs targeted at very small patient 
populations. It is common for these products to be priced up to $500,000 per annum. 
This research reviewed the pricing of these unique products (including trends) and 
explored alternative funding strategies that have been negotiated (e.g. outcome 
contracts) and/or are being proposed (e.g. reimbursement methods) by payers to 
manage their budgets. METHODS: We conducted research on the publicly available 
data on unique biopharma products and their pricing through literature and inter-
